|Bid||4.3700 x 900|
|Ask||4.3700 x 900|
|Day's Range||4.1700 - 4.8000|
|52 Week Range||2.4900 - 12.9000|
|Beta (5Y Monthly)||1.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 14, 2022 - Feb 18, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Aug 28, 1996|
|1y Target Est||15.00|
VIENNA, Va., August 19, 2022--CEL-SCI corporation announces Phase 3 Multikine head and neck cancer results posted on clinicaltrials.gov.
VIENNA, Va., August 15, 2022--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2022, as well as key clinical and corporate developments.
VIENNA, Va., August 08, 2022--CEL-SCI Corporation (NYSE American: CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors.